Risk-Free™ Immune Checkpoints

What Are Immune Checkpoints?

Immune Checkpoints are proteins that act as T cell receptor (TCR) co-signaling partners that deliver either positive or negative signals to T lymphocytes. Under normal conditions, these proteins are critical for self-tolerance, but in tumors these immune checkpoint proteins can allow the tumor to evade the anti-tumor immune response. Blocking the actions of these proteins can produce a potent anti-tumor response. This new approach to cancer treatment is referred to as immunotherapy or immuno-oncology.

ProSci Inc. has developed several new classes of reagents that can be used to study the actions of multiple immune checkpoint proteins such as CTLA-4, PD-1, and its ligands PD-L1 and PD-L2. These classes of products include highly validated Risk-Free™ mouse monoclonal antibodies (mAbs), llama single domain antibodies, rabbit polyclonal antibodies, as well as recombinant proteins, tissue and cell slides and lysates. These products should prove useful in basic research, diagnostics, and drug development in the field of immuno-oncology.

What is Risk-Free™?

In a 2008 study, fewer than half of over 6,000 commercially available antibodies recognized only their targets [1,2], leading to an estimated $350 million wasted on "bad" antibodies [1]. ProSci Inc. is proud to announce the release of their new line of Risk-Free™ antibodies.

Risk-Free™ Immune Checkpoint Monoclonal Antibodies

ProSci's Risk-Free™ antibodies are monoclonal antibodies made to improve in vitro studies. Unlike antibodies developed using proteins made in yeast or bacteria, these antibodies are developed with antigens expressed in mammalian cell lines, giving the most native post-translational modifications to the protein. Risk-Free™ means they have been extensively evaluated and are guaranteed to work for a variety of applications such as ELISA, Flow Cytometry, Western Blotting, Immunocytochemistry, Immunofluorescence, and Immunohistochemistry. Multiple mAbs are available to the researcher to allow the selection of the best application-specific antibodies.

Risk-Free™ Immune Checkpoint Antibody Sets

Many antibodies work well one application but not in others despite detecting the same proteins. Because the target antigen may be denatured or inaccessible depending on the technique or preparation, scientists must search and test multiple antibodies for one application and repeat the process again for a different application. ProSci has recognized this issue and has released Risk-Free™ Antibody Sets.

Immune Checkpoint Targets

Risk-Free™ Monoclonal Antibodies

TargetAvailability
PD-1 Available
CTLA-4 Available
PD-L1 Available
PD-L2 Available
CD80 Available
TIGIT Available
LIGHT (TNFSF14) August 2017
VISTA (B7-H5) September 2017
LAG3 September 2017
B7-H3 (CD276) September 2017
TIM3 September 2017
ICOSLG October 2017
ICOS November 2017
TMIGD2 November 2017

Single Domain Monoclonal Antibodies

TargetAvailability
PD-1 Available
PD-L1 Available
CTLA-4 September 2017
TIGIT September 2017
TIM3 October 2017
PD-L2 Inquire
LAG3 Inquire

References

1. Berglund L, Bjorling E, Oksvold P, et al. "A gene-centric human protein atlas for expression profiles based on antibodies."Mol. Cell Proteomics 2008; 7:2019-27.

2. Bradbury A, Plucktun, et al. "Standardize antibodies used in research."Nature 2015; 518:27-9.